CL2011002444A1 - Pharmaceutical composition containing a liposome and the active compound eribulin or its pharmacologically permissible salt in the internal phase of the liposome; and the method of manufacturing the liposome composition. - Google Patents

Pharmaceutical composition containing a liposome and the active compound eribulin or its pharmacologically permissible salt in the internal phase of the liposome; and the method of manufacturing the liposome composition.

Info

Publication number
CL2011002444A1
CL2011002444A1 CL2011002444A CL2011002444A CL2011002444A1 CL 2011002444 A1 CL2011002444 A1 CL 2011002444A1 CL 2011002444 A CL2011002444 A CL 2011002444A CL 2011002444 A CL2011002444 A CL 2011002444A CL 2011002444 A1 CL2011002444 A1 CL 2011002444A1
Authority
CL
Chile
Prior art keywords
liposome
eribulin
manufacturing
active compound
internal phase
Prior art date
Application number
CL2011002444A
Other languages
Spanish (es)
Inventor
Hiroshi Kikuchi
Kenji Hyodo
Hiroshi Ishihara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66221437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002444(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2011002444A1 publication Critical patent/CL2011002444A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composición farmacéutica que contiene un liposoma y el compuesto activo eribulina, o su sal farmacológicamente permisible, en la fase interna del liposoma; y método de manufactura de la composición del liposoma.Pharmaceutical composition containing a liposome and the active compound eribulin, or its pharmacologically permissible salt, in the internal phase of the liposome; and method of manufacturing the liposome composition.

CL2011002444A 2009-03-30 2011-09-30 Pharmaceutical composition containing a liposome and the active compound eribulin or its pharmacologically permissible salt in the internal phase of the liposome; and the method of manufacturing the liposome composition. CL2011002444A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16465309P 2009-03-30 2009-03-30
JP2009082521 2009-03-30

Publications (1)

Publication Number Publication Date
CL2011002444A1 true CL2011002444A1 (en) 2012-04-09

Family

ID=66221437

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002444A CL2011002444A1 (en) 2009-03-30 2011-09-30 Pharmaceutical composition containing a liposome and the active compound eribulin or its pharmacologically permissible salt in the internal phase of the liposome; and the method of manufacturing the liposome composition.

Country Status (2)

Country Link
CL (1) CL2011002444A1 (en)
RU (1) RU2476216C1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011009632A (en) 2009-03-30 2011-10-19 Eisai R&D Man Co Ltd Liposome composition.
JP7015237B2 (en) 2016-04-28 2022-02-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 How to control tumor growth
US10722466B2 (en) * 2016-10-28 2020-07-28 Les Laboratoires Servier Liposomal formulation for use in the treatment of cancer
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL91664A (en) * 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US6214865B1 (en) * 1998-06-17 2001-04-10 Eisai Co., Ltd. Macrocyclic analogs and methods of their use and preparation

Also Published As

Publication number Publication date
RU2476216C1 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
PE20151519A1 (en) LIPOSOME COMPOSITION
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
CR20120177A (en) NEW COMPOUNDS OF SPIROPIPERIDINE AND PHARMACEUTICAL USE OF THE SAME FOR THE TREATMENT OF DIABETES
PH12015502628B1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CL2013000437A1 (en) Pharmaceutical dosage form with breaking strength of at least 500 n, containing an active ingredient, 5 to 70% by weight of an inorganic salt, at least 30% by weight of a polyalkylene oxide, wherein the active ingredient is integrated in a controlled release matrix comprising inorganic salt and polyalkylene oxide.
MX2015016344A (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease.
ECSP12011930A (en) NEW SPYROPIPERIDINE COMPOUNDS
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
ECSP088904A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
CL2012002356A1 (en) Heterocyclic acid compounds derived from bisyl-linked aryltriazolones, vasopressin receptor inhibitors v1a and v2; preparation procedure; pharmaceutical composition; and its use to treat and / or prevent acute and chronic heart failure, hyponatremia, among others.
CY1119798T1 (en) FORM IV IV Hydrochloride Ibabradine
UY33396A (en) 5-FLUORO-1H-REPLACED PIRAZOLOPIRIDINES AND ITS USE
IN2015DN00185A (en)
CL2013002504A1 (en) Solid coated pharmaceutical preparation comprising at least one active ingredient and because the coating has a thickness of 0.1 to 100 nm, preferably 0.3 to 50 nm and more preferably 0.5 to 35 nm; and its method of preparation
CO6362012A2 (en) CLOHYDRATE OF DIHYDRATED NALMEFEN
EA201200484A1 (en) PHARMACEUTICAL COMPOSITION WITH EXISTING SUBSTANCES - METHORMIN AND SYTAGLIPTIN OR VILDAGLIPTIN
CL2011002862A1 (en) Use of perhexiline or a pharmaceutically acceptable salt thereof to prepare a drug useful in the treatment of hypertrophic cardiomyopathy (HCM).
MX2013011926A (en) Glycoside derivatives and uses thereof.
GT201400042A (en) BENZOTIAZOLONA COMPOSITE
CL2011002444A1 (en) Pharmaceutical composition containing a liposome and the active compound eribulin or its pharmacologically permissible salt in the internal phase of the liposome; and the method of manufacturing the liposome composition.
EA201200319A1 (en) INTRODUCTION OF ACTIVATED CARBON IN THE RENDERING OF EMERGENCY ASSISTANCE IN THE CASE OF OVERDOSE OF DAGIGATRAN ETEXILATE
EA201301021A1 (en) APPLICATION OF A COMPOSITION CONTAINING AMBROADABLE CONTAINING AMBROXOL
UY31856A (en) NEW ASSOCIATION OF ACTIVE INGREDIENTS CONTAINING AN ANTIFLAMMATORY, NON-STEROID PHARMACO AND A COLCHICOSIDE DERIVATIVE
CO6511242A2 (en) COMBINATION AND COMPOSITION CONTAINING AN ANTIMICROBIAL, A GLUCOCORTICOID AND AN ANTIMYCTIC
CL2010001230A1 (en) Method for inhibiting melanogenesis comprising administering a steroidal compound; pharmaceutical composition; topical formulation, useful in the treatment of a disease or condition that involves melanogenesis.